Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.15 +8.79%

+$2.32 today

Market cap
$1.83B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.30M

Average 0.34M

Balance Sheet

Inspect the capital base behind the business.

Assets

$194.78M

FY 2025 · Annual

Liabilities

$371.42M

FY 2025 · Annual

Equity

-$176.63M

FY 2025 · Annual

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$237.4M
Short-term Investments$220.1M
Other Current$6.5M
Total Current Assets$464.0M
PP&E (Net)$1.5M
Other Non-current$2.3M
Total Non-current Assets$3.8M
Total Assets$467.8M

Analysis

Selected assets total $467.8M for Latest. The largest visible component is Cash & Equivalents at $237.4M, about 50.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
4Statement of changes in beneficial ownershipSep 25, 2026
3Initial statement of beneficial ownershipSep 25, 2026

How much cash does COAG have?

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) reported $87.97M in cash and equivalents in fiscal 2025.

How much debt does COAG carry?

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) reported $1.22M of total debt, with net debt of -$86.75M.